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GLUCOSE UTILIZATION IN THE HUMAN EPIDERMIS:
ITS CONTROL BY HEXOKINASE*
KENNETH M. HALPHIN, M.D. AND AKIRA OHKAWARA, M.D.
Glucose transport into the epidermal cell
does not seem to be hindered by its passage
through the cell membrane. The evidence for
this consists of the finding of free glucose within
the epidermis by Sehragger (1). In addition,
insulin which would be expected to affect the
process of membrane transport if this posed
a barrier to glucose entry has no effect on
glucose entry into epidermis (2).
An appreciable intracellular concentration
of free glucose Would not be possible if the
enzyme responsible for phosphorylating glu-
cose, ie. hexokinase, Were able to utilize all of
the glucose being presented to it. The finding
of free glucose within the epidermis therefore
implies that hexokinase activity is limiting the
amount of glucose Which is phosphorylated to
glueose-6-phosphate. All subsequent metabolic
processes (glycogen formation, glyeolysis, Krebs
cycle, pentose shunt, etc.) require glueose-6-
phosphate as their beginning material. By
limiting the amount of glucose-6-phosphate
Which is formed from free glucose, the hexo-
kinase reaction is acting to control the amount
of carbohydrate substrate Which is available to
the cell for all these other processes. It con-
stitutes a block in carbohydrate metabolism
which affects the entire economy of the cell.
There are two quite different ways to assess
the activity of this reaction. One is to measure
the disappearance of glucose from a glucose
containing physiologic medium when an epi-
dermal slice is allowed to float upon the sur-
face. The cell is using all the glucose which
disappears. This glucose must be phosphoryl-
ated by hexokinase to be used and the rate of
disappearance of glucose is a direct measure of
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the hexokinase reaction. These preparations
are presumably fairly close to the actual in
vivo situation. Measurements of this kind
indicate a rate of 0.20—0.4 mtm (millimiero-
mole) of glucose used per minute per milli-
gram of fresh epidermis (3—5).
The second method is to homogenize the
tissue and to measure hexokinase activity in
the homogenate. These in vitro assays are done
under optimal conditions of high substrate
concentrations and the absence of inhibitors.
They measure the maximal rate of substrate
turnover the amount of enzyme present within
the tissue is capable of producing. We find a
rate of 3.0 mm of glucose turned into glucose-6-
phosphate per minute per milligram of fresh
epidermis at 37°C.
It is quite obvious from the discrepancy in
the figures given by the two methods that con-
ditions within the epidermal slice (and also
presumably in vivo) do not correspond with
the optimal conditions used in the in vitro assay.
In vivo although the amount of enzyme present
in 1 milligram of epidermis is enough to phos-
phorylate 3.0 mtm of glucose per minute it is
prevented from doing so either by a lack of
adequate substrate or by the presence of inhi-
bitors.
This study was done to define the conditions
in vivo which prevent hexokinase from acting
at its maximal rate. We have quantitated the
amount of the various substrates and inhibitors
present in the epidermis and studied the effects
such concentrations might be expected to have
on human epidermal hexokinase.
MATEnIAL5
Epidermis from the back of normal male stu-
dents aged 20—25 was removed by the use of an
eleetrokeratome (6). Samples weighed 30—100
milligrams and contained from 0—25% dermal con-
tamination. Anesthesia was not used.
Epidermis to be used for substrate or inhibitor
concentration determinations was frozen in liquid
N, within 5—10 seconds of removal. It was later
weighed and homogenized in cold 0.6 N perchloric
acid while still frozen. The perehlorie acid extract
was neutralized with 2 N KOH and the insoluble
potassium perehlorate removed by centrifugation.
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The resulting clear extract was used for all sub-
strate and inhibitor concentration determinations
and is referred to hereafter as the "acid extract".
Epidermis to be used for enzyme kinetic studies
was weighed and homogenized in 10 >< its volume
of cold .05 M "tris" buffer pH 7.4 containing .003
M Mg Cl2 and .0005 M EDTA. This is referred to
hereafter as "epidermal homogenate".
METHODS
All analyses and reactions were done fluorometri-
cally using a Farrand model 2A fluorometer with
a microammeter attachment which recorded
directly into a potentiometric recorder. These
analyses depend upon the fluorescence produced
by the reduced pyridine nucleotides TPNH and
DPNH. These nucleotides act as cofactors in many
oxidation-reduction reactions and serve as useful
indicators. Their oxidized forms do not absorb or
fluoresce while the reduced forms absorb light of
340 mg wavelength and then fluoresce at approxi-
mately 460 mm. By the use of suitable filers this
fluorescent wavelength can be isolated and its mag-
nitude is a direct measure of the amount of
reduced nucleotide in the solution. For a fuller
discussion of this method see Lowry (7). All assays
were done at 25° C.
Glucose-6-phosphote ossoy.—Two m1 (micro-
liters) of glucose-6-phosphate dehydrogenase (0.1
unit) and 10 m1 of TPN (0.1 mm) are added to 1
cc of tris buffer pH 7.4 and the fluorescence deter-
mined. 10 m1 of "acid extract" are then added and
the increase in fluorescence is noted. This increase
is due to the production of TPNH during the
oxidation of glucose-6-phosphate to 6-phospho-
gluconate by glucose-fl-phosphate dehydrogenase.
The instrument must be calibrated so that the
fluorescence reading can be converted into mm of
TPNH or DPNH present. The amount of TPNH
found is a direct measure of the amount of glucose-
6-phosphate originally added to the cuvette.
Glucose ossoy.—Ten m1 of TPN (0.1 mm), 2 m1
of glucose-6-phosphate dehydrogenase (0.1 ml.) 10
m1 of ATP (0.7 mm) and 2 m1 of hcxokinase (0.1
unit) are added to 1 cc of tris buffer pH 7.4 con-
taining .003 M MgCl2 and .0005 M EDTA. The
fluorescence is determined initially and after the
addition of 10 m1 of "acid extract". The glucose
in the extract is turned into glucose-fl-phosphate
by the action of hexokinase. Glucose-fl-phosphate
formed is immediately turned into 6-phospho-
gluconate by glucose-fl-phosphate dehydrogenase
with the simultaneous reduction of TPN to TPNH.
The amount of TPNH formed is a direct measure
of the amount of glucose originally in the "acid
extract".
A TP ossoy.—This assay is exactly like the
glucose assay with the single change of substituting
10 m1 of glucose (0.5 mm) for the ATP.
ADP essoy.—Phosphoenolpyruvate (0.7 mm) and
pyruvic kinase (0.1 unit) are added to 10 m1 of
"acid extract" in 1 cc of buffer. The ADP is
changed to ATP by this reaction and an equivalent
amount of pyruvate is formed from the phospho-
enolpyruvate. The pyruvate so formed is deter-
mined by adding 10 m1 of DPNH (0.7 mm) and 2
m1 of lactic dehydrogenase to the tube. This
enzyme converts pyruvate to lactate with the
simultaneous oxidation of an equivalent amount
of DPNH and this decrease in fluorescence is
measured.
Hexokiaose essoy.—Ten m1 of "homogenate" are
added to 1 cc of buffer containing .003 M MgCi2,
.0005 M EDTA, glucose-fl-phosphate dehydro-
genase (.01 unit) TPN (0.1 mm) and ATP (0.7
mm). The reaction is started by adding glucose (0.5
mm) and the rate of glucose-fl-phosphate formation
(actually TPNH formation) is followed on the
recorder. The slope of the increase is a measure of
the hexokinase activity under maximal substrate
conditions.
RESULTS AND DISCUSSION
Effect of glucose concentration on hexoki-
nose activity.—Figure 1 shows the change in
hexokinase activity which occurs with various
glucose concentrations. It can be seen that
maximal activity is obtained at a concentration
of approximately 0.5 ffm/cc. Figure 2 is a plot
of 1/substrate concentration vs. I/velocity. The
Km (substrate concentration giving ½ the
maximal velocity) for glucose derived from
this plot is 4.1 x 10° M.
Table 1 shows the concentration of glucose
as determined in human epidermis. These
values are above the concentrations which are
EFFECT OF GLUCOSE ON HEXOKINASE ACTIVITY
2.0
•________•_
.67'
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Concentration
ATP O.7pM/cc
0.4 Mgt1 .003M
EDTA r .00051*1
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Glucose concentration — pM/cc
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Substance
Concentration
pm/cc
mpm/mg intra-
epidermis cellularH20
% of maximal
in iro
activity
Glucose (11). ..
ATP (9)
Glucose-6-phos-
phate (8)
ADP (7)
Phosphate (2)...
1.25 0.36
0.28 0.07
<0.1
1.6 0.5
11.8 1.3
1.88
0.42
0.1
2.4
17.7
100
80
? See text
28
70
All of above conditions added to-
gether 25
* The number in parenthesis refers to the num-
ber of subjects.
needed to give maximal rates of hexokinase
activity as seen in Figure 1. Depression of
hexokinase activity in vivo cannot be ascribed
to a lack of adequate glucose.
Effect of ATP concentration on hexokinase
activity —Figure 3 shows the change in hexo-
kinase activity which occurs with various ATP
concentrations. Maximal activity requires a
concentration of 0.7 p.m/cc. Km for ATP =
1 x 10_s M as seen in Figure 2.
The epidermal concentration of ATP as seen
in Table 1 is 0.28 mp.m/mg. This is equivalent
to a fluid concentration of ATP of 0.42-p.m/
cc. This concentration according to Figure 3
would reduce the activity of hexokinase to 1.45
EFFECT OF ATP AND GLUCOSE
ON HEXOKINASE ACTIVITY EFFECT OF ATP ON HEXOKINASE ACTIVITY
Ii /V)
MpM/min
Glucose
4.1 x I0 M
AlP
K. I x I0 M
V 1.80
£
.6
Fic. 2
TABLE 1
0.4
I I I
0.4 0.8 1.2
AT P concentration
Fxc. 3
EFFECT OF ADP ON HEXOKINASE ACTIVITY
1.6
Concentration
\ Glucose a055 tiM/cc\ AlP :O35pM/cc
. 1.2 \ Mq a.003M
EDTA a0005M
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0.4
•
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E F FE CT OF H ON hexokinase is similar to the brain enzyme the
H E xo IN A SE ACTIVITY measured concentration of glucose-6-phosphate
would have very little effect. This point, how-
ever, cannot be directly answered as yet.
lOpH
FJG.5
mm/min/mg from its maximum of 1.80
mm/min/mg. This reduction is significant and
may explain a part of the reduced activity seen
in vivo. However, the rate is still 80% of maxi-
mal and is therefore not the principal con-
trolling factor.
Effect of Glucose-6-phosphate concentration
on hexo/cinse activity.—Unfortunately our assay
system precludes dynamic measurements of the
effect of this compound. However, the epider-
mal concentration of glucose-6-phosphate as
seen in Table 1 is very low. Brain hexokinase
is inhibited 50% by a glucose-6-phosphate con-
centration of 0.4 ILm/cc (8). If epidermal FIG. 7
EFFECT OF Mg CONCENTRATION ON
HEXOKINASE ACTIVITY
I.6\N
I I I I I
0.04 0.08 0.12 0.16
Mg'+ concentration — molar
Fio. 6
EFFECT OF
PHOSPHATE CONCENTRATION
ON HEXOKINASE ACTIVITY
6 8
80 160
Phosphate concentration — zM/cc
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Effect of ADP concentration on hexokina.se
activity—Figure 4 demonstrates the effect of
changing ADP concentrations. 50% inhibition
occurs at a concentration of 1.0 tm/cc which is
equivalent to a Ki (concentration at which
velocity is reduced from its maximal by 50%)
of 1 >< 10 M. As seen in Table 1, the tissue
concentration of ADP is 1.6 mtm/mg or 2.4
p.m/cc when considering the intracellular fluid
concentration. This concentration will reduce
the hexokinase reaction to approximately 28%
of its maximal value and is sufficient in itself to
explain most of the in vivo inhibition.
Effect of pH on hexokina.se activity—Figure
5 shows the pH activity curve of hexokinase.
A drop in pH from 7.4 to 7.0 would result in a
50% inhibition. It is difficult to estimate
whether such an effect would occur in vivo,
but it would certainly not be an efficient con-
trol mechanism.
Effect of Mg concentration on hexokinase
activity —Maximal activity of the enzyme is
obtained at magnesium concentrations of 0.002—
0.007 M as seen in Figure 6. It seems unlikely
that wide variations of the intracellular ionic
strength would occur, but these have not been
measured.
Effect of PO4 concentration on hexokinase
activity.—Phosphate is a known inhibition of
hexokinase as seen in Figure 7. A concentration
of 15 FLm/cc (1.5 x 10 M) results in 25%
inhibition. Measurement of phosphate in hu-
man epidermis gives values of 17.7 p.m/cc and
this may cause a significant reduction. It is
difficult, however, to imagine very wide varia-
tions occurring in the concentration of this
compound, but such a controlling factor must
be considered.
Other pathways of glucose utilization—In
other organisms and tissues the direct oxidation
of glucose to gluconic acid or its reduction to
sorbitol are known to occur. We have looked
for these pathways in epidermis and have been
unable to demonstrate either the direct oxida-
tion or a reduction to sorbitol.
Effect of insulin on hexokinase activity—No
effect could be demonstrated at concentrations
of 1 unit/cc.
Total inhibitory effects—Adding the various
substrates and inhibitors together in physiologic
concentrations might be expected to give addi-
tive effects which would reduce the activity of
hexokinase to even lower levels than the 28%
of maximal velocity covered by the ADP con-
centration above. However, when this is done,
the total inhibition of hexokinase activity is
still only 25% of maximal. Evidently the inhibi-
tory effects are not additive and perhaps phos-
phate and ADP act at the same site.
SUMMARY AND CONCLUSIONS
By comparing the in vivo concentrations of
various substrates and inhibitors of hexokinasc
activity with their demonstrable effects as
shown in vitro, it has been possible to demon-
strate the factors which account for the in vivo
inhibition of hexokinase. This inhibition is due
to the low concentration of ATP and especially
the high concentration of ADP and inorganic
phosphate.
Since hexokinase acts as a gate to allow the
free flow of glucose into the various metabolic
channels of the cell, ADP and perhaps inorganic
phosphate are in effect controlling the entire
cellular economy. Any process which lowers the
ADP or the phosphate concentration will cause
a direct rise in the amount of glucose being uti-
lized by the cell. Increased glycolysis and
Krebs cycle functioning which utilize ADP and
manufacture ATP will therefore increase the
glucose utilization by the cell while conversely
an increase in synthetic processes which break
ATP down into ADP will tend to lower the
utilization of glucose.
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